Prognostic Value of NOX4 Expression in Cancer Patients: A Systematic Review and Meta-analysis

Table 2

Subgroup analysis and meta-regression of the association between NOX4 expression and overall survival in cancer patients.

Subgroup					Heterogeneity		Meta-regression
	Number of studies	Number of patients	Pooled HR (95% CI)	p value	I^2 (%)	p value	p value
Cancer type							0.09
GI cancer	4	1537	1.83 (1.39-2.42)	< 0.001	40.90	0.18
HCC	3	738	0.67 (0.36-1.27)	0.23	85.89	< 0.001
Others	2	400	1.51 (1.13-2.03)	0.01	0.00	0.37
Sample size							0.23
Less than 200	4	498	1.66 (1.13-2.43)	0.01	72.20	0.01
More than 200	5	2177	1.03 (0.57-1.86)	0.86	90.7	< 0.001
NOX4 detection							0.77
mRNA	4	1950	1.20 (0.63-2.29)	0.29	89.61	< 0.001
Protein	5	725	1.39 (0.82-2.34)	0.16	89.10	< 0.001
Survival analysis							0.62
MVA	5	830	1.44 (0.85-2.44)	0.16	83.72	< 0.001
UVA	4	1845	1.15 (0.62-2.15)	0.26	94.59	< 0.001

CI, confidence interval; GI, gastrointestinal; HCC, hepatocellular carcinoma; HR, hazard ratio; MVA, multivariate analysis; NOX4, NADPH oxidase 4; UVA, univariate analysis.